子宫肌瘤与维生素D关系的研究进展

doi:10.12280/gjfckx.20210021

摘要/Abstract

摘要：

子宫肌瘤是妇科常见的良性肿瘤,严重影响女性的生活质量。目前临床治疗子宫肌瘤的思路是根据个体差异制定不同的保守治疗方案或手术治疗方案,但这些治疗方案都存在弊端。多年来,医学界一直在寻找更佳的治疗子宫肌瘤的方案,维生素D与子宫肌瘤之间的关系也因此被发现。作为一种类固醇类化合物,维生素D在人体各器官组织中起到重要作用。已证实的与维生素D有关的妇产科疾病包括不孕症、多囊卵巢综合征和早产等。近十年的研究证实,人体内维生素D水平降低是子宫肌瘤发生、发展的危险因素之一,目前也有研究发现补充维生素D及其类似物可以起到治疗子宫肌瘤的作用。

关键词: 维生素D, 子宫, 肌瘤, 受体,骨化三醇, 药物疗法

Abstract:

Uterine fibroids are common benign tumors in gynecology, which seriously affect women′s quality of life. The current idea of clinical treatment of uterine fibroids is to formulate different conservative treatment plans or surgical treatment plans based on individual differences, but these treatment plans have drawbacks. For many years, the medical profession has been looking for better treatments for uterine fibroids, and the relationship between vitamin D and uterine fibroids has also been discovered. As a steroid compound, vitamin D plays an important role in various organs and tissues of the human body. The confirmed obstetrics and gynecology diseases related to vitamin D include infertility, polycystic ovary syndrome and premature delivery. Studies in the past decade have confirmed that reduced levels of vitamin D in the human body are one of the risk factors for the occurrence and development of uterine fibroids. Some current studies have also found that drug supplementation with vitamin D and its analogues can play a role in the treatment of uterine fibroids.

Key words: Vitamin D, Uterus, Myoma, Receptors,calcitriol, Drug therapy

王子豪, 周建政, 王美雲, 杨玲. 子宫肌瘤与维生素D关系的研究进展[J]. 国际妇产科学杂志, 2021, 48(5): 543-547.

WANG Zi-hao, ZHOU Jian-zheng, WANG Mei-yun, YANG Ling. Research Progress on the Relationship between Uterine Fibroids and Vitamin D[J]. Journal of International Obstetrics and Gynecology, 2021, 48(5): 543-547.

参考文献 33

[1]	Stewart EA, Laughlin-Tommaso SK, Catherino WH, et al. Uterine fibroids[J]. Nat Rev Dis Primers, 2016,2:16043. doi: 10.1038/nrdp.2016.43. doi: 10.1038/nrdp.2016.43
[2]	De La Cruz MS, Buchanan EM. Uterine Fibroids: Diagnosis and Treatment[J]. Am Fam Physician, 2017,95(2):100-107.
[3]	Pavone D, Clemenza S, Sorbi F, et al. Epidemiology and Risk Factors of Uterine Fibroids[J]. Best Pract Res Clin Obstet Gynaecol, 2018,46:3-11. doi: 10.1016/j.bpobgyn.2017.09.004. doi: S1521-6934(17)30137-2 pmid: 29054502
[4]	Voulgaris N, Papanastasiou L, Piaditis G, et al. Vitamin D and aspects of female fertility[J]. Hormones(Athens), 2017,16(1):5-21. doi: 10.14310/horm.2002.1715. doi: 10.14310/horm.2002.1715
[5]	Arslan S, Akdevelioğlu Y. The Relationship Between Female Reproductive Functions and Vitamin D[J]. J Am Coll Nutr, 2018,37(6):546-551. doi: 10.1080/07315724.2018.1431160. doi: 10.1080/07315724.2018.1431160
[6]	Ciebiera M, Ali M, Zgliczyńska M, et al. Vitamins and Uterine Fibroids: Current Data on Pathophysiology and Possible Clinical Relevance[J]. Int J Mol Sci, 2020,21(15):5528. doi: 10.3390/ijms21155528. doi: 10.3390/ijms21155528
[7]	Mohammadi R, Tabrizi R, Hessami K, et al. Correlation of low serum vitamin-D with uterine leiomyoma: a systematic review and meta-analysis[J]. Reprod Biol Endocrinol, 2020,18(1):85. doi: 10.1186/s12958-020-00644-6. doi: 10.1186/s12958-020-00644-6
[8]	Islam MS, Ciavattini A, Petraglia F, et al. Extracellular matrix in uterine leiomyoma pathogenesis: a potential target for future therapeutics[J]. Hum Reprod Update, 2018,24(1):59-85. doi: 10.1093/humupd/dmx032. doi: 10.1093/humupd/dmx032
[9]	Jayes FL, Liu B, Feng L, et al. Evidence of biomechanical and collagen heterogeneity in uterine fibroids[J]. PLoS One, 2019,14(4):e0215646. doi: 10.1371/journal.pone.0215646. doi: 10.1371/journal.pone.0215646
[10]	Aleksandrovych V, Białas M, Pasternak A, et al. Identification of uterine telocytes and their architecture in leiomyoma[J]. Folia Med Cracov, 2018,58(3):89-102. doi: 10.24425/fmc.2018.125075. doi: 10.24425/fmc.2018.125075 pmid: 30521514
[11]	Baranov VS, Osinovskaya NS, Yarmolinskaya MI. Pathogenomics of Uterine Fibroids Development[J]. Int J Mol Sci, 2019,20(24):6151. doi: 10.3390/ijms20246151. doi: 10.3390/ijms20246151
[12]	El Andaloussi A, Al-Hendy A, Ismail N, et al. Introduction of Somatic Mutation in MED12 Induces Wnt4/β-Catenin and Disrupts Autophagy in Human Uterine Myometrial Cell[J]. Reprod Sci, 2020,27(3):823-832. doi: 10.1007/s43032-019-00084-7. doi: 10.1007/s43032-019-00084-7
[13]	Crabtree JS, Jelinsky SA, Harris HA, et al. Comparison of human and rat uterine leiomyomata: identification of a dysregulated mammalian target of rapamycin pathway[J]. Cancer Res, 2009,69(15):6171-6178. doi: 10.1158/0008-5472.CAN-08-4471. doi: 10.1158/0008-5472.CAN-08-4471 pmid: 19622772
[14]	Al-Hendy A, Diamond MP, Boyer TG, et al. Vitamin D3 Inhibits Wnt/β-Catenin and mTOR Signaling Pathways in Human Uterine Fibroid Cells[J]. J Clin Endocrinol Metab, 2016,101(4):1542-1551. doi: 10.1210/jc.2015-3555. doi: 10.1210/jc.2015-3555 pmid: 26820714
[15]	Halder SK, Osteen KG, Al-Hendy A. Vitamin D3 inhibits expression and activities of matrix metalloproteinase-2 and -9 in human uterine fibroid cells[J]. Hum Reprod, 2013,28(9):2407-2416. doi: 10.1093/humrep/det265. doi: 10.1093/humrep/det265
[16]	Philips N, Samuel P, Keller T, et al. Beneficial Regulation of Cellular Oxidative Stress Effects, and Expression of Inflammatory, Angiogenic, and the Extracellular Matrix Remodeling Proteins by 1α,25-Dihydroxyvitamin D3 in a Melanoma Cell Line[J]. Molecules, 2020,25(5):1164. doi: 10.3390/molecules25051164. doi: 10.3390/molecules25051164
[17]	Ali M, Shahin SM, Sabri NA, et al. 1,25 Dihydroxyvitamin D3 Enhances the Antifibroid Effects of Ulipristal Acetate in Human Uterine Fibroids[J]. Reprod Sci, 2019,26(6):812-828. doi: 10.1177/1933719118812720. doi: 10.1177/1933719118812720
[18]	Ito I, Waku T, Aoki M, et al. A nonclassical vitamin D receptor pathway suppresses renal fibrosis[J]. J Clin Invest, 2013,123(11):4579-4594. doi: 10.1172/JCI67804. doi: 10.1172/JCI67804
[19]	Hemida MA, AbdElmoneim NA, Hewala TI, et al. Vitamin D Receptor in Breast Cancer Tissues and Its Relation to Estrogen Receptor Alpha (ER-α) Gene Expression and Serum 25-hydroxyvitamin D Levels in Egyptian Breast Cancer Patients: A Case-control Study[J]. Clin Breast Cancer, 2019,19(3):e407-e414. doi: 10.1016/j.clbc.2018.12.019. doi: 10.1016/j.clbc.2018.12.019
[20]	Ali M, Shahin SM, Sabri NA, et al. Hypovitaminosis D exacerbates the DNA damage load in human uterine fibroids, which is ameliorated by vitamin D3 treatment[J]. Acta Pharmacol Sin, 2019,40(7):957-970. doi: 10.1038/s41401-018-0184-6. doi: 10.1038/s41401-018-0184-6
[21]	Puchar A, Feyeux C, Luton D, et al. Therapeutic management of uterine fibroid tumors[J]. Minerva Ginecol, 2016,68(4):466-476. pmid: 26698838
[22]	Donnez J, Dolmans MM. Uterine fibroid management: from the present to the future[J]. Hum Reprod Update, 2016,22(6):665-686. doi: 10.1093/humupd/dmw023. doi: 10.1093/humupd/dmw023
[23]	Donnez J, Donnez O, Matule D, et al. Long-term medical management of uterine fibroids with ulipristal acetate[J]. Fertil Steril, 2016,105(1):165- 173.e4. doi: 10.1016/j.fertnstert.2015.09.032. doi: 10.1016/j.fertnstert.2015.09.032
[24]	Middelkoop MA, Bet PM, Drenth JPH, et al. Risk-efficacy balance of ulipristal acetate compared to surgical alternatives[J]. Br J Clin Pharmacol, 2021,87(7):2685-2697. doi: 10.1111/bcp.14708. doi: 10.1111/bcp.14708 pmid: 33341097
[25]	Ciebiera M, Vitale SG, Ferrero S, et al. Vilaprisan, a New Selective Progesterone Receptor Modulator in Uterine Fibroid Pharmaco-therapy-Will it Really be a Breakthrough?[J]. Curr Pharm Des, 2020,26(3):300-309. doi: 10.2174/1381612826666200127092208. doi: 10.2174/1381612826666200127092208
[26]	Charoenngam N, Holick MF. Immunologic Effects of Vitamin D on Human Health and Disease[J]. Nutrients, 2020,12(7):2097. doi: 10.3390/nu12072097. doi: 10.3390/nu12072097
[27]	Bläuer M, Rovio PH, Ylikomi T, et al. Vitamin D inhibits myometrial and leiomyoma cell proliferation in vitro[J]. Fertil Steril, 2009,91(5):1919-1925. doi: 10.1016/j.fertnstert.2008.02.136. doi: 10.1016/j.fertnstert.2008.02.136 pmid: 18423458
[28]	Ciavattini A, Delli Carpini G, Serri M, et al. Hypovitaminosis D and "small burden" uterine fibroids: Opportunity for a vitamin D supplementation[J]. Medicine(Baltimore), 2016,95(52):e5698. doi: 10.1097/MD.0000000000005698. doi: 10.1097/MD.0000000000005698
[29]	Hajhashemi M, Ansari M, Haghollahi F, et al. The effect of vitamin D supplementation on the size of uterine leiomyoma in women with vitamin D deficiency[J]. Caspian J Intern Med, 2019,10(2):125-131. doi: 10.22088/cjim.10.2.125. doi: 10.22088/cjim.10.2.125 pmid: 31363390
[30]	Arjeh S, Darsareh F, Asl ZA, et al. Effect of oral consumption of vitamin D on uterine fibroids: A randomized clinical trial[J]. Complement Ther Clin Pract, 2020,39:101159. doi: 10.1016/j.ctcp.2020.101159. doi: 10.1016/j.ctcp.2020.101159
[31]	Corachán A, Ferrero H, Escrig J, et al. Long-term vitamin D treatment decreases human uterine leiomyoma size in a xenograft animal model[J]. Fertil Steril, 2020,113(1):205-216.e4. doi: 10.1016/j.fertnstert.2019.09.018. doi: 10.1016/j.fertnstert.2019.09.018
[32]	夏维波, 章振林, 林华, 等. 维生素D及其类似物临床应用共识[J]. 中华骨质疏松和骨矿盐疾病杂志, 2018,11(1):1-19. doi: 10.3969/j.issn.1674-2591.2018.01.001. doi: 10.3969/j.issn.1674-2591.2018.01.001
[33]	Ciebiera M, Ali M, Prince L, et al. The Evolving Role of Natural Compounds in the Medical Treatment of Uterine Fibroids[J]. J Clin Med, 2020,9(5):1479. doi: 10.3390/jcm9051479. doi: 10.3390/jcm9051479